SSRI Recommendations During Pregnancy
Sertraline is the recommended first-line SSRI to switch to during pregnancy due to its established safety profile, lower risk of adverse outcomes, and minimal transfer to the fetus. 1
Safety Profile of SSRIs in Pregnancy
First-Line Option: Sertraline
- Sertraline has a favorable safety profile for use during pregnancy with benefits typically outweighing potential risks 1
- Minimal excretion in breast milk (<10% of maternal daily dose) 1
- Low placental transfer to infants (only 25-33% of maternal concentrations) 2
- Limited evidence of teratogenicity compared to other SSRIs 3
Second-Line Options
- Citalopram has mixed evidence regarding safety but generally shows fewer associations with negative outcomes when controlled for maternal depression 3
- Fluoxetine and paroxetine have stronger associations with adverse outcomes and should be avoided 3
Risks to Consider When Switching
Potential Risks of SSRIs During Pregnancy
- Neonatal adaptation syndrome may occur with third-trimester exposure, characterized by:
- Persistent pulmonary hypertension of the newborn (PPHN) has been associated with SSRI use, though studies show mixed results 4
Risks of Untreated Depression
- Premature birth
- Decreased breastfeeding initiation
- Increased risk of maternal depression relapse 1
- These risks often outweigh potential medication risks
Monitoring and Management
During Pregnancy
- Monitor sertraline plasma concentrations during pregnancy as there is significant interindividual variation (up to 10-fold) 2
- Consider that sertraline concentrations may decrease during pregnancy (67% relative difference between second trimester and postpartum) 2
- Dose adjustments may be needed due to pharmacokinetic changes during pregnancy 1
Postpartum and Breastfeeding
- Monitor breastfed infants for irritability, poor feeding, or sleep disturbances 1
- Exercise particular caution with premature or low birth weight infants 1
- Sertraline is considered safe during breastfeeding due to very low concentrations in breast milk 1, 3
Clinical Pearls and Pitfalls
Common Pitfalls
- Abruptly discontinuing antidepressants during pregnancy can lead to significant increase in depression relapse 4
- Failing to consider the risks of untreated depression when making medication decisions
- Not monitoring for dose adjustments needed during pregnancy due to pharmacokinetic changes
Important Considerations
- The decision to use SSRIs during pregnancy should balance maternal mental health needs against potential fetal risks
- Long-term studies have not identified adverse neurodevelopmental outcomes among infants born to women treated with SSRIs during pregnancy 1
- When switching from another antidepressant, consider a gradual cross-taper to minimize withdrawal symptoms and maintain mood stability
By following these recommendations and switching to sertraline when an SSRI is needed during pregnancy, clinicians can help manage depression and anxiety while minimizing potential risks to both mother and baby.